Affiliation:
1. Collegium Medicum Jagiellonian University, Kraków, Poland
Abstract
The use of the National Health Fund databases as a source of real-world evidence
Patient medical records and administrative healthcare databases are possible sources of real-world evidence (RWE), i.e., evidence on the potential benefits and risks of a medical product. RWE can complement the evidence from randomized clinical trials. The wide range of information collected by the National Health Fund (NFZ) and the Ministry of Health in Poland ensures the versatility of the data that cover almost all patients treated in Poland. In addition to administrative data (without detailed information about patients and their disease), electronic medical records of some patient groups can be obtained from special programs (e.g., KOS-Zawał) or the System of Monitoring Drug Programs (SMPT). Low usage (only 37 studies) but high usability of NFZ databases as a source of RWE were identified. Joint analysis of data from administrative databases and SMPT can increase the credibility of the study, but limits the study to only patients treated within the Drug Programs.
Publisher
Uniwersytet Jagiellonski - Wydawnictwo Uniwersytetu Jagiellonskiego
Reference55 articles.
1. 1. ISPOR. 2022-2023 Top 10 HEOR Trends Report, 2022, https://www.ispor.org/heor-resources/about-heor/top-10-heor-trends (dostęp: 12.05.2022).
2. 2. Gavrielov-Yusim N., Friger M., Use of Administrative Medical Databases in Population-based Research, "Journal of Epidemiology and Community Health" 2014; 68 (3): 283-287.
3. 3. Zarebska-Michaluk D., Jaroszewicz J., Rogalska M., et al., Effectiveness of Tocilizumab With and Without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study, "Journal of Inflammation Research" 2021; 14: 3359-3366.
4. 4. Offord C., The Surgisphere Scandal: What Went Wrong? Scientist, październik 2020, https://www.the-scientist.com/features/thesurgisphere-scandal-what-went-wrong-67955 (dostęp: 12.05.2022).
5. 5. How Real World Evidence Was Used to Support Approval of Ibrance for Male Breast Cancer, "The Cancer Letter" 2019; 45: 7-10, https://cancerletter.com/the-cancer-letter/20190419_2/ (dostęp: 20.02.2022).